June 5, 2017 / 1:22 PM / 3 months ago

BRIEF-‍Beigene presents initial phase 1 data on BGB-A317 combined with BGB-290

June 5 (Reuters) - Beigene Ltd

* ‍Beigene presents initial phase 1 data on anti-PD-1 antibody BGB-A317 combined with PARP inhibitor BGB-290 at 2017 American Society for Clinical Oncology Annual Meeting​

* Beigene Ltd - ‍safety analysis suggested that combination of BGB-A317 and BGB-290 was generally well-tolerated in patients with advanced solid tumors​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below